Forest Laboratories (FRX)
Forest Laboratories Market Cap: 8.863B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
FRX Market Cap Rankings
| Overall | 89th percentile | 509 of 4650 |
| Sector | 91st percentile | 44 of 525 in Healthcare |
| Industry | 90th percentile | 4 of 42 in Drug Manufacturers - Other |
FRX Market Cap Range, Past 5 Years
| Minimum | 6.623B | Mar 2009 |
| Maximum | 14.61B | Jun 2007 |
| Average | 9.558B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these FRX related companies
FRX News
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
May 25, 12:32PM Street Insider
May 25, 12:32PM Street Insider
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
May 14, 8:00AM Business Wire
May 14, 8:00AM Business Wire
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROE
Apr 24, 3:44AM Benzinga
Apr 24, 3:44AM Benzinga
Ironwood (IRWD), Forest (FRX) Repot Three-Month Extension on FDA Linaclotide Review
Apr 23, 6:26AM Street Insider
Apr 23, 6:26AM Street Insider
Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
Apr 23, 2:30AM Business Wire
Apr 23, 2:30AM Business Wire
Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates
Apr 18, 12:55PM Street Insider
Apr 18, 12:55PM Street Insider
UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT for Forest Laboratories
Apr 18, 11:07AM Benzinga
Apr 18, 11:07AM Benzinga
Market Wrap Video + Additions to Watch List http://stks.co/3OUz including: $CHS $CROX $DECK $FRX $FSLR $MIPS $SRZ $TRMB
about 41 days ago by StockTiger
about 41 days ago by StockTiger
Forest Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Apr 18, 9:00AM Seeking Alpha
Apr 18, 9:00AM Seeking Alpha
Market Wrap Video + Additions to Watch List http://stks.co/3O64 including: $CHS $CROX $DECK $FRX $FSLR $MIPS $SRZ $TRMB
about 41 days ago by StockTiger
about 41 days ago by StockTiger
$FRX Provides Fiscal Year 2013 EPS Guidance in the Range of $0.90-$1.05 Per Share. http://stks.co/3NIN
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX reports Bystolic sales @ $96.9M, Savella sales @ $25.3M. R&D spending: $213.9M
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX Q4 Earnings: Adjusted EPS 78c vs consensus of 70c. Revenue: $1.06B vs consensus of $1.02B
about 42 days ago by abubnic
about 42 days ago by abubnic
$FRX flashing golden cross. Possibly setting up a bull flag. http://stks.co/3G8v
about 51 days ago by tradewithpete
about 51 days ago by tradewithpete
News related to $FRX, currently +0.5% since open: 'Fight over hypertension pill leads to lawsuit' http://stks.co/2r04
about 76 days ago by TradeBot
about 76 days ago by TradeBot
$FRX reports 2nd set of positive results in Phase III trials of anti-depressant drug, Levomilnacipran. http://stks.co/2hug
about 83 days ago by abubnic
about 83 days ago by abubnic
News related to $FRX, currently -0.2% since open: 'Ironwood Pharma falls as analyst cuts rating' http://stks.co/2g6B
about 85 days ago by TradeBot
about 85 days ago by TradeBot
http://stks.co/2arQ upwards earnings revisions Post Earnings Revision Drift $BIIB,$DV,$FRX,$LSCC,$XLNK (run 2 weeks ago)
about 91 days ago by secretbonus
about 91 days ago by secretbonus
$FRX get EU appro for Colobreathe cystic fibrosis inhalation treatment for chronic lung infection in kids >6yrs old. http://stks.co/2ZWP
about 92 days ago by abubnic
about 92 days ago by abubnic
Listen to $FRX Forest Laboratories, Inc. at Citi Global Health Care Conference - live at 09:00 AM, ondemand after - http://stks.co/2ZUN
about 92 days ago by earningscast
about 92 days ago by earningscast
WSJ| FDA Panel Supports Approval Of $FRX Lung Drug Aclidinium. http://stks.co/2Yvo
about 93 days ago by abubnic
about 93 days ago by abubnic
$FRX and Almirall: FDA Advisory Committee Recommends Approval of Aclidinium Bromide for Treatment of COPD. http://stks.co/2Yvl
about 93 days ago by abubnic
about 93 days ago by abubnic
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FRX | 33.38 | +0.05 | +0.15% | 8.863B |
| FRT | 98.59 | -0.60 | -0.60% | 6.277B |
| FRED | 14.12 | +0.12 | +0.86% | 525.69M |
| FRD | 10.08 | +0.01 | +0.10% | 68.54M |
| FRC | 32.85 | -0.10 | -0.30% | 4.272B |
| FRBK | 1.91 | -0.05 | -2.55% | 49.60M |
| FRA | 14.27 | -0.08 | -0.56% | |
| FCO | 13.49 | -0.06 | -0.44% | |
| FCNCA | 166.83 | +1.83 | +1.11% | 1.715B |
| FCLF | 6.00 | +0.23 | +3.99% | 46.32M |